Etoposide Phosphate
drugOn this page
Also known as BMY 40481BMY-40481EtopophosEtopophos preservative freeVepesideVP-16VP16
Summary
Etoposide Phosphate (CHEMBL1200645) is an approved small molecule; indicated across 31 conditions including lymphoma and hodgkins lymphoma.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 31 conditions
- Clinical trials: 91
- Chemistry: 668.5 Da · C29H33O16P
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200645 |
| Name | Etoposide Phosphate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 6918092 |
| Molecular formula | C29H33O16P |
| Molecular weight | 668.5 |
| InChIKey | LIQODXNTTZAGID-OCBXBXKTSA-N |
SMILES: C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)OP(=O)(O)O)OC)O)O
IUPAC name: [4-[(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenyl] dihydrogen phosphate
Also known as: BMY 40481, BMY-40481, Etopophos, Etopophos preservative free, Etoposide phosphate, Vepeside, VP-16, VP16, ETOPOSIDE PHOSPHATE, etoposide phosphate
Patent coverage: 4,340 distinct patent families (10,214 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
31 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| lymphoma | 3 | MONDO:0005062 | EFO:0000574 |
| Hodgkins lymphoma | 3 | MONDO:0004952 | EFO:0000183 |
| acute lymphoblastic leukemia | 3 | MONDO:0004967 | EFO:0000220 |
| carcinoma | 3 | MONDO:0004993 | EFO:0000313 |
| neuroblastoma | 3 | MONDO:0005072 | EFO:0000621 |
| central nervous system neoplasm | 3 | MONDO:0006130 | EFO:1000158 |
| lung neoplasm | 3 | MONDO:0021117 | MONDO:0008903 |
| ganglioneuroblastoma | 3 | MONDO:0005035 | EFO:0000502 |
| diffuse large B-cell lymphoma | 3 | MONDO:0018905 | EFO:0000403 |
| leukemia | 2 | MONDO:0005059 | EFO:0000565 |
| rhabdomyosarcoma | 2 | MONDO:0005212 | EFO:0002918 |
| medulloblastoma | 2 | MONDO:0007959 | EFO:0002939 |
| non-Hodgkin lymphoma | 2 | MONDO:0018908 | EFO:0005952 |
| glioma | 2 | MONDO:0021042 | MONDO:0100342 |
| B-cell acute lymphoblastic leukemia | 2 | MONDO:0004947 | EFO:0000094 |
| T-cell acute lymphoblastic leukemia | 2 | MONDO:0004963 | EFO:0000209 |
| Burkitt lymphoma | 2 | MONDO:0007243 | EFO:0000309 |
| mantle cell lymphoma | 2 | MONDO:0018876 | EFO:1001469 |
| acute myeloid leukemia | 1 | MONDO:0018874 | EFO:0000222 |
| plasma cell myeloma | 1 | MONDO:0009693 | EFO:0001378 |
| anaplastic oligodendroglioma | 1 | MONDO:0016696 | EFO:0002501 |
| peritoneal neoplasm | 1 | MONDO:0006901 | MONDO:0002087 |
| fallopian tube neoplasm | 1 | MONDO:0021092 | MONDO:0002158 |
| ovarian cancer | 1 | MONDO:0008170 | MONDO:0008170 |
| myelodysplastic syndrome | 1 | MONDO:0018881 | EFO:0000198 |
| plasma cell neoplasm | 1 | MONDO:0004959 | EFO:0000200 |
| myeloid leukemia | 1 | MONDO:0004643 | MONDO:0004643 |
4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 91.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 33 |
| PHASE3 | 18 |
| PHASE1 | 16 |
| PHASE4 | 7 |
| Not specified | 7 |
| PHASE1/PHASE2 | 5 |
| PHASE2/PHASE3 | 4 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00199004 | PHASE4 | COMPLETED | Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab |
| NCT00199017 | PHASE4 | COMPLETED | German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults |
| NCT00199056 | PHASE4 | COMPLETED | German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99) |
| NCT00199082 | PHASE4 | COMPLETED | Newly Diagnosed Mature B-ALL, Burkitt’s Lymphoma and Other High-grade Lymphoma in Adults |
| NCT00526175 | PHASE4 | COMPLETED | LAL-BR/2001: Study Treatment to Low Risk ALL |
| NCT01873807 | PHASE4 | UNKNOWN | HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL |
| NCT02036489 | PHASE4 | COMPLETED | Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia |
| NCT01949129 | PHASE2/PHASE3 | RECRUITING | Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia |
| NCT02306161 | PHASE3 | ACTIVE_NOT_RECRUITING | Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma |
| NCT02375204 | PHASE3 | ACTIVE_NOT_RECRUITING | Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors |
| NCT03126916 | PHASE3 | RECRUITING | Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) |
| NCT04759586 | PHASE3 | ACTIVE_NOT_RECRUITING | Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma |
| NCT05675410 | PHASE3 | RECRUITING | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab |
| NCT05991388 | PHASE2/PHASE3 | RECRUITING | A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma |
| NCT06188676 | PHASE3 | RECRUITING | Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL |
| NCT00011921 | PHASE3 | UNKNOWN | Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer |
| NCT00293358 | PHASE3 | COMPLETED | Combination Chemotherapy and Radiation Therapy in Treating Patients With Germ Cell Tumors in the Brain |
| NCT00302003 | PHASE3 | COMPLETED | Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin’s Lymphoma |
| NCT00410631 | PHASE3 | UNKNOWN | Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma |
| NCT00417053 | PHASE3 | UNKNOWN | Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant |
| NCT00433498 | PHASE3 | COMPLETED | Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer |
| NCT00499018 | PHASE3 | UNKNOWN | Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma |
| NCT01026220 | PHASE3 | COMPLETED | Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma |
| NCT01228331 | PHASE2/PHASE3 | COMPLETED | Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL |
| NCT01423500 | PHASE3 | UNKNOWN | ALL-SCT BFM International- HSCT in Children and Adolescents With ALL |
| NCT01423747 | PHASE3 | UNKNOWN | Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia |
| NCT01457040 | PHASE2/PHASE3 | COMPLETED | Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic Leukemia |
| NCT02137096 | PHASE3 | TERMINATED | Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma |
| NCT02881086 | PHASE3 | COMPLETED | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment |
| NCT01356290 | PHASE2 | RECRUITING | Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors |
| NCT01871766 | PHASE2 | ACTIVE_NOT_RECRUITING | Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy |
| NCT02106988 | PHASE2 | ACTIVE_NOT_RECRUITING | Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma |
| NCT02866136 | PHASE2 | ACTIVE_NOT_RECRUITING | Conservative Treatments of Retinoblastoma |
| NCT03113500 | PHASE2 | ACTIVE_NOT_RECRUITING | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma |
| NCT04663347 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) |
| NCT06905509 | PHASE2 | RECRUITING | Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma |
| NCT07138001 | PHASE2 | NOT_YET_RECRUITING | Phase 2 Clinical Trial of KH617 |
| NCT00002880 | PHASE2 | COMPLETED | Etoposide in Treating Patients With Relapsed Non-Hodgkin’s Lymphoma |
| NCT00003064 | PHASE1/PHASE2 | UNKNOWN | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT00005797 | PHASE2 | COMPLETED | Bone Marrow Transplant in Treating Patients With Hematologic Cancers |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).